| http://www.w3.org/ns/prov#value | - IA: Trials were eligible for inclusion provided they (1) randomized men with BPH to receive B-sitosterol preparations in comparison to placebo or other BPH medications, and (2) included clinical outcomes such as urologic symptom scales, symptoms, or urodynamic measurements.DATA COLLECTION AND ANALYSIS: Information on patients, interventions, and outcomes was extracted by at least two independent r
|
